Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response.
Sidders B, Zhang P, Goodwin K, O'Connor G, Russell DL, Borodovsky A, Armenia J, McEwen R, Linghu B, Bendell JC, Bauer TM, Patel MR, Falchook GS, Merchant M, Pouliot G, Barrett JC, Dry JR, Woessner R, Sachsenmeier K. Sidders B, et al. Among authors: russell dl. Clin Cancer Res. 2020 May 1;26(9):2176-2187. doi: 10.1158/1078-0432.CCR-19-2183. Epub 2020 Jan 17. Clin Cancer Res. 2020. PMID: 31953314 Clinical Trial.
STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti-PD-L1.
Proia TA, Singh M, Woessner R, Carnevalli L, Bommakanti G, Magiera L, Srinivasan S, Grosskurth S, Collins M, Womack C, Griffin M, Ye M, Cantin S, Russell D, Xie M, Hughes A, Deng N, Mele DA, Fawell S, Barry S, Reimer C, Barrett JC, McCoon P. Proia TA, et al. Clin Cancer Res. 2020 Dec 1;26(23):6335-6349. doi: 10.1158/1078-0432.CCR-20-1066. Epub 2020 Sep 17. Clin Cancer Res. 2020. PMID: 32943458
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors.
Staniszewska AD, Armenia J, King M, Michaloglou C, Reddy A, Singh M, San Martin M, Prickett L, Wilson Z, Proia T, Russell D, Thomas M, Delpuech O, O'Connor MJ, Leo E, Angell H, Valge-Archer V. Staniszewska AD, et al. Oncoimmunology. 2022 Jun 18;11(1):2083755. doi: 10.1080/2162402X.2022.2083755. eCollection 2022. Oncoimmunology. 2022. PMID: 35756843 Free PMC article.
Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors.
Lim EA, Bendell JC, Falchook GS, Bauer TM, Drake CG, Choe JH, George DJ, Karlix JL, Ulahannan S, Sachsenmeier KF, Russell DL, Moorthy G, Sidders BS, Pilling EA, Chen H, Hattersley MM, Das M, Kumar R, Pouliot GP, Patel MR. Lim EA, et al. Among authors: russell dl. Clin Cancer Res. 2022 Nov 14;28(22):4871-4884. doi: 10.1158/1078-0432.CCR-22-0612. Clin Cancer Res. 2022. PMID: 36044531 Free PMC article. Clinical Trial.
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
Besse B, Pons-Tostivint E, Park K, Hartl S, Forde PM, Hochmair MJ, Awad MM, Thomas M, Goss G, Wheatley-Price P, Shepherd FA, Florescu M, Cheema P, Chu QSC, Kim SW, Morgensztern D, Johnson ML, Cousin S, Kim DW, Moskovitz MT, Vicente D, Aronson B, Hobson R, Ambrose HJ, Khosla S, Reddy A, Russell DL, Keddar MR, Conway JP, Barrett JC, Dean E, Kumar R, Dressman M, Jewsbury PJ, Iyer S, Barry ST, Cosaert J, Heymach JV. Besse B, et al. Among authors: russell dl. Nat Med. 2024 Mar;30(3):716-729. doi: 10.1038/s41591-024-02808-y. Epub 2024 Feb 13. Nat Med. 2024. PMID: 38351187 Free PMC article. Clinical Trial.
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.
Falchook GS, Reeves J, Gandhi S, Spigel DR, Arrowsmith E, George DJ, Karlix J, Pouliot G, Hattersley MM, Gangl ET, James GD, Thompson J, Russell DL, Patel B, Kumar R, Lim E. Falchook GS, et al. Among authors: russell dl. Cancer Immunol Immunother. 2024 Mar 2;73(4):72. doi: 10.1007/s00262-024-03640-6. Cancer Immunol Immunother. 2024. PMID: 38430405 Free PMC article. Clinical Trial.
Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study.
Matsubara N, Kusuhara S, Yamamoto N, Sudo K, Yanagita M, Murayama K, Kawasumi H, Russell DL, Yin D, Shimizu T. Matsubara N, et al. Among authors: russell dl. Cancer Chemother Pharmacol. 2024 Apr;93(4):341-352. doi: 10.1007/s00280-023-04605-9. Epub 2023 Dec 13. Cancer Chemother Pharmacol. 2024. PMID: 38086998 Free PMC article.
Corrigendum to "Excitatory synaptic structural abnormalities produced by templated aggregation of α-syn in the basolateral amygdala" [Neurobiology of Disease 199 (2024) 106595].
Gcwensa NZ, Russell DL, Long KY, Brzozowski CF, Liu X, Gamble KL, Cowell RM, Volpicelli-Daley LA. Gcwensa NZ, et al. Among authors: russell dl. Neurobiol Dis. 2025 Jan;204:106757. doi: 10.1016/j.nbd.2024.106757. Epub 2025 Jan 6. Neurobiol Dis. 2025. PMID: 39779046 Free article. No abstract available.
Drinking water quality impacts oocyte viability and embryo development.
Winstanley YE, Gonzalez MB, Andreas E, Connaughton H, Bergen J, Ween M, Russell DL, Shearer CJ, Robertson SA, Robker RL. Winstanley YE, et al. Among authors: russell dl. Front Reprod Health. 2024 Aug 6;6:1394099. doi: 10.3389/frph.2024.1394099. eCollection 2024. Front Reprod Health. 2024. PMID: 39166174 Free PMC article.
138 results